170737-93-6

Basic information

• Product Name: (2-CHLORO-4-METHOXYPHENYL)ACETONITRILE
• Synonyms: (2-CHLORO-4-METHOXYPHENYL)ACETONITRILE;2-(2-chloro-4-methoxyphenyl)acetonitrile;2-Chloro-4-methoxybenzeneacetonitrile
• CAS NO: 170737-93-6
• Molecular Formula: C₉H₈ClNO
• Molecular Weight: 181.62
• Mol File: 170737-93-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 42-44°C
• Boiling Point: 300.749 °C at 760 mmHg
• Flash Point: 135.689 °C
• Appearance: White or dark brown powder
• Density: 1.198 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: Sealed in dry,Room Temperature
• Water Solubility: Insoluble in water.
• CAS DataBase Reference: (2-CHLORO-4-METHOXYPHENYL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-CHLORO-4-METHOXYPHENYL)ACETONITRILE(170737-93-6)
• EPA Substance Registry System: (2-CHLORO-4-METHOXYPHENYL)ACETONITRILE(170737-93-6)

Safety Data

• Hazard Codes: Xi,T
• Statements: 20/21/22-36/37/38
• Safety Statements: 9-26-36/37
• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 170737-93-6(Hazardous Substances Data)

Usage

Uses

2-Chloro-4-methoxyphenylacetonitrile is used as a raw material and an intermediate in organic synthesis.

InChI:InChI=1/C9H8ClNO/c1-12-8-3-2-7(4-5-11)9(10)6-8/h2-3,6H,4H2,1H3

Upstream product

• 54788-17-9 2-chloro-4-methoxybenzyl bromide 
• 101080-63-1 2-chloro-4-methoxybenzyl chloride 
• 143-33-9 sodium cyanide 
• 13435-20-6 tetraethylammoniumcyanide 

Downstream Products

• 848400-80-6 1-(2-chloro-4-methoxyphenyl)cyclopropanecarbonitrile 
• 1100592-51-5 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1338727-94-8 5-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methyl-2,3-dihydrofuro[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine 
• 441060-02-2 (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine 
• 817636-91-2 8-chloro-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 
• 817636-90-1 8-hydroxy-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 
• 1338727-99-3 3-[2-chloro-4-(difluoromethoxy)phenyl]-N-(1-ethylpropyl)-2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 857262-72-7 3-chloro-4-[8-(1-ethylpropylamino)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-3-yl]-phenol 
• 1338728-00-9 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2-methyl-6,7-dihydrofuro[2,3-d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 1338727-93-7 3-(2-chloro-4-methoxyphenyl)-2-methyl-6,7-dihydrofuro[2,3-d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 1236305-61-5 2-(2-chloro-4-methoxy-phenyl)-2-isopropyl-3-methyl-butyronitrile 
• 847604-18-6 methyl 2-(2-chloro-4-methoxyphenyl)acetate 
• 91367-09-8 2-(2-chloro-4-methoxyphenyl)acetic acid 

Relevant articles and documents

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS

The invention relates to compounds represented by Formula (I):, and to prodrugs thereof, pharmaceutically salts or solvates of said compounds or said prodrugs, wherein each of X1-X5 and R1-R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).